Evidence map›Paper›PMID 36646114›Full record

ArticleNature2023

Molecular fate-mapping of serum antibody responses to repeat immunization.

Ariën Schiepers, Marije F L van 't Wout, Allison J Greaney, Trinity Zang, Hiromi Muramatsu, Paulo J C Lin, Ying K Tam, Luka Mesin, Tyler N Starr, Paul D Bieniasz and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
32.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 168 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Clonal dynamics of germinal center refueling by secondary immunization.bioRxiv : the preprint server for biology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Ariën SchiepersLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-5185-364X
Marije F L van 't WoutLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY, USA.
Allison J GreaneyBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Trinity ZangLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1544-1493
Paulo J C LinAcuitas Therapeutics, Vancouver, British Columbia, Canada.
Ying K TamAcuitas Therapeutics, Vancouver, British Columbia, Canada.ORCID 0000-0002-4083-5251
Luka MesinLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY, USA.
Tyler N StarrBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-2368-3719
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1008-6242
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-1267-3408
Gabriel D VictoraLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY, USA. victora@rockefeller.edu.ORCID 0000-0001-8807-348X
Rockefeller University · USAcuitas Therapeutics (Canada) · CAFred Hutch Cancer Center · USHoward Hughes Medical Institute · USUniversity of Pennsylvania · US

Funding

The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responsesP01AI165075 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2022 to 2023
$10.7M
Quantifying Cell-Cell Interactions in the Immune System by Trans-Synaptic LabelingDP1AI144248 · NIAID · ROCKEFELLER UNIVERSITY · PI VICTORA, GABRIEL D · 2018 to 2022
$5.9M
Dynamics of Antigen-Driven Selection in Germinal CentersR01AI119006 · NIAID · ROCKEFELLER UNIVERSITY · PI Gabriel D Victora · 2017 to 2026
$5.7M
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responsesR01AI153064 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michela Locci, Norbert Pardi · 2020 to 2026
$4.2M
Molecular control of germinal center selection and affinity maturationR01AI139117 · NIAID · ROCKEFELLER UNIVERSITY · PI Gabriel D Victora · 2018 to 2026
$3.9M
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNAR01AI146101 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PARDI, NORBERT · 2019 to 2023
$3.1M
Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1M
NIAID NIH HHS DP1 AI144248NIAID NIH HHS P01 AI165075NIAID NIH HHS R01 AI119006NIAID NIH HHS R01 AI139117NIAID NIH HHS R01 AI141707NIAID NIH HHS R01 AI146101NIAID NIH HHS R01 AI153064Wellcome Trust
6 · The paper itself

Abstract

The protective efficacy of serum antibodies results from the interplay of antigen-specific B cell clones of different affinities and specificities. These cellular dynamics underlie serum-level phenomena such as original antigenic sin (OAS)-a proposed propensity of the immune system to rely repeatedly on the first cohort of B cells engaged by an antigenic stimulus when encountering related antigens, in detriment to the induction of de novo responses

Indexed as

Antibody FormationB-LymphocytesImmunization, SecondaryAntibodies, ViralAntigens, ViralHumansInfluenza VaccinesSARS-CoV-2VaccinationViral VaccinesAntibodies, ViralAntigens, ViralInfluenza VaccinesViral Vaccines

Identifiers

PMID36646114
PMCPMC10023323
OpenAlexW4316507331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.